胰高血糖素样肽-1减肥应用的伦理探讨  

An Ethical Discussion on the Use of Glucagon-like Peptide-1 for Weight Loss

作　　者：程欣瑞 翟晓梅[1] CHENG Xinrui;ZHAI Xiaomei(School of Population Medicine and Public Health,Chinese Academy of Medical Sciences/Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院/北京协和医学院群医学及公共卫生学院,北京100730

出　　处：《医学与哲学》2024年第9期16-19,共4页Medicine and Philosophy

摘　　要：针对胰高血糖素样肽-1受体激动剂类药物在治疗肥胖方面的医学价值和潜在滥用的现实情况,深入探讨了该类药物在非糖尿病肥胖治疗中的超适应证应用及其伦理问题,包括医疗资源的合理分配、患者知情同意的重要性以及社会审美标准对医疗决策的影响。并针对上述伦理问题,提出了包括加强药物处方规范、提高公众药物知识、确保患者知情同意等建议。旨在促进胰高血糖素样肽-1受体激动剂类药物在肥胖治疗中的合理及伦理使用,保障医疗伦理和患者安全。This article explores the medical value of glucagon-like peptide-1 receptor agonist analogs and the potential abuse in obesity treatment.It also provides insights into the use of glucagon-like peptide-1 receptor agonist analogs for non-diabetic obesity and discusses related ethical issues.These issues include the equitable allocation of healthcare resources,the importance of patients'informed consent,and the influence of societal aesthetic standards on medical decision-making.Finally,the article makes recommendations to address these issues,including strengthening prescription regulations,improving public awareness of medications,and ensuring patients'informed consent.These recommendations aim to promote the rational and ethical use of glucagon-like peptide-1 receptor agonist analogs in obesity treatment and to safeguard medical ethics and patient safety.

关 键 词：胰高血糖素样肽-1 受体激动剂 超适应证用药 减肥 伦理分析 

分 类 号：R-05[医药卫生]